Company intelligence / Profile preview

Hubei Biocause Heilen Pharmaceutical

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Hubei Biocause Heilen Pharmaceutical is a leading Chinese pharmaceutical company specializing in the production and export of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company has been inspected multiple times by US FDA and EU GMP authorities. Its products are exported to over 85 countries globally, including highly regulated markets such as the USA and EU. Key products include abiraterone acetate, ibuprofen, milrinone, fludarabine phosphate, granisetron hydrochloride, cladribine, torsemide, among others.

Therapeutic areas: RheumatologyPsychiatryNeurologyOncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

thiotriazoline

Unknown

Beyond the preview

Go deeper on Hubei Biocause Heilen Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hubei Biocause Heilen Pharmaceutical.

Explore the full profile